Pazopanib Hydrochloride CAS 635702-64-6 Ubunyulu > 99.0% (HPLC) API Factory

Inkcazelo emfutshane:

Igama leKhemikhali: Pazopanib Hydrochloride

CAS: 635702-64-6

Imbonakalo: Imhlophe ukuya kwiPowder etyheli kancinane

Ubunyulu: >99.0% (HPLC)

I-Tyrosine kinase receptor inhibitor yonyango lwe-renal cell carcinoma okanye i-sarcoma ye-soft soft

Umgangatho ophezulu we-API, iMveliso yoRhwebo

Inquiry: alvin@ruifuchem.com

Thumela i-imeyile kuthi

Iinkcukacha zeMveliso

Iimveliso ezinxulumeneyo

Iithegi zeMveliso

Inkcazo:

Ubonelelo lwabavelisi ngoBusulungekileyo obuPhezulu kunye noMgangatho oZinzileyo
Igama leKhemikhali: Pazopanib Hydrochloride
CAS: 635702-64-6
I-Tyrosine kinase receptor inhibitor yonyango oluphezulu lwe-renal cell carcinoma okanye i-soft tissue sarcoma efumene i-chemotherapy yangaphambili.
Umgangatho ophezulu we-API, iMveliso yoRhwebo

Iipropati zeMichiza:

Igama leMchiza	I-Pazopanib Hydrochloride
Izithethantonye	I-Pazopanib HCl;GW786034 HCl;I-Votrient;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Hydrochloride
Inombolo yeCAS	635702-64-6
Inombolo yeCAT	RF-API93
Ubume beStokhwe	Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram
Ifomula yeemolekyuli	I-C21H23N7O2S.ClH
Ubunzima beMolekyuli	473.987
Ukunyibilika	I-DMSO
Indawo yokunyibilika	300.0 ~ 304.0℃
Uphawu	Ruifu Chemical

Iinkcukacha:

Into	Iinkcukacha
Imbonakalo	Umgubo oMhlophe ukuya kumthubi kancinane
Ukuchongwa	I-spectrum yokufunxa ye-infraed yesampulu yovavanyo ihambelana naleyo yomgangatho
Intsalela kwi-Ignition	≤0.50%
Nakuphi na Ukungacoceki komntu	≤0.30%
Ukungcola ngokupheleleyo	≤1.50%
Iintsimbi ezinzima	≤10ppm
Ubunyulu / Indlela yokuHlalutya	≥99.0% (HPLC)
Umgangatho woVavanyo	Umgangatho woShishino
Ukusetyenziswa	I-API, iTyrosine kinase receptor inhibitor

Ukupakishwa kunye noGcino:

Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.

Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.

Izinto eziluncedo:

FAQ:

Isicelo:

I-Pazopanib Hydrochloride (CAS 635702-64-6) i-multi-tyrosine kinase inhibitor ye-vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, iplatelet-derived growth factor receptor (PDGFR) -α kunye - I-β, i-fibroblast factor receptor (FGFR) -1 kunye -3, i-cytokine receptor (Kit), i-interleukin-2 i-receptor-inducible T-cell kinase (Itk), iprotheni ye-lymphocyte-specific tyrosine kinase (Lck), kunye ne-transmembrane glycoprotein receptor tyrosine kinase (cFms).I-In vitro, pazopanib inhibited ligand-induced autophosphorylation ye-VEGFR-2, Kit, kunye ne-PDGFR-beta receptors.Kwi-vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis kwimodeli yempuku, kunye nokukhula kwezinye i-tumor xenografts yabantu kwiimpuku.Yavunywa i-renal cell carcinoma yi-US Food and Drug Administration ngo-2009 kwaye ithengiswa phantsi kwegama lorhwebo iVotrient ngumenzi wechiza, i-GlaxoSmithKline.I-Votrient yi-kinase inhibitor eboniswe kunyango lwezigulane ezine: 1) i-renal cell carcinoma ephezulu.2) i-sarcoma yezicubu ezithambileyo eziye zafumana ichemotherapy yangaphambili.